JP2021523912A - 粘液透過性ペプチド、送達ビヒクルおよび治療方法 - Google Patents

粘液透過性ペプチド、送達ビヒクルおよび治療方法 Download PDF

Info

Publication number
JP2021523912A
JP2021523912A JP2020564152A JP2020564152A JP2021523912A JP 2021523912 A JP2021523912 A JP 2021523912A JP 2020564152 A JP2020564152 A JP 2020564152A JP 2020564152 A JP2020564152 A JP 2020564152A JP 2021523912 A JP2021523912 A JP 2021523912A
Authority
JP
Japan
Prior art keywords
peptide
less
delivery vehicle
mucus
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020564152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523912A5 (https=
JPWO2019222400A5 (https=
Inventor
ムビージ アハマド，
ムビージ アハマド，
ティモシー ポール デイ，
ティモシー ポール デイ，
カサンドラ コールマン，
カサンドラ コールマン，
シーシー ジュー，
シーシー ジュー，
イスマイル ハーフェズ，
イスマイル ハーフェズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Particella Inc
Original Assignee
Particella Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Particella Inc filed Critical Particella Inc
Publication of JP2021523912A publication Critical patent/JP2021523912A/ja
Publication of JP2021523912A5 publication Critical patent/JP2021523912A5/ja
Publication of JPWO2019222400A5 publication Critical patent/JPWO2019222400A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020564152A 2018-05-15 2019-05-15 粘液透過性ペプチド、送達ビヒクルおよび治療方法 Withdrawn JP2021523912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671709P 2018-05-15 2018-05-15
US62/671,709 2018-05-15
PCT/US2019/032484 WO2019222400A2 (en) 2018-05-15 2019-05-15 Mucus-penetrating peptides, delivery vehicles and methods of therapy

Publications (3)

Publication Number Publication Date
JP2021523912A true JP2021523912A (ja) 2021-09-09
JP2021523912A5 JP2021523912A5 (https=) 2022-05-16
JPWO2019222400A5 JPWO2019222400A5 (https=) 2022-05-16

Family

ID=68540758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564152A Withdrawn JP2021523912A (ja) 2018-05-15 2019-05-15 粘液透過性ペプチド、送達ビヒクルおよび治療方法

Country Status (7)

Country Link
US (1) US20210177982A1 (https=)
EP (1) EP3796892A2 (https=)
JP (1) JP2021523912A (https=)
CN (1) CN112367974A (https=)
AU (1) AU2019269590A1 (https=)
CA (1) CA3100020A1 (https=)
WO (1) WO2019222400A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230023615A1 (en) * 2019-12-13 2023-01-26 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
US20230346700A1 (en) * 2020-02-19 2023-11-02 University Of Florida Research Foundation, Incorporated Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
EP4259099A1 (en) 2020-12-14 2023-10-18 Particella, Inc. Biological delivery systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US176111A (en) 1876-04-11 Improvement in car-couplings
EP2253326B1 (en) * 2008-02-28 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for transnasal administration
WO2012109363A2 (en) * 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CA2863632C (en) * 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
AU2013256064B2 (en) * 2012-05-03 2018-01-04 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
KR101669203B1 (ko) * 2014-06-18 2016-10-25 한국과학기술연구원 신규 세포투과성 펩타이드 및 이의 용도
WO2018013907A1 (en) * 2016-07-15 2018-01-18 Board Of Regents, The University Of Texas System Mucus-penetrating peptides and screening assay
US11090391B2 (en) * 2016-09-16 2021-08-17 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery

Also Published As

Publication number Publication date
EP3796892A2 (en) 2021-03-31
WO2019222400A3 (en) 2020-02-13
CA3100020A1 (en) 2019-11-21
CN112367974A (zh) 2021-02-12
WO2019222400A2 (en) 2019-11-21
AU2019269590A1 (en) 2020-12-03
US20210177982A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
JP7772597B2 (ja) 生物学的送達ビヒクルのための組成物及び方法
US20230023615A1 (en) Compositions and methods for biological delivery vehicles
US20210177982A1 (en) Mucus-penetrating peptides, delivery vehicles and methods of therapy
US20190351071A1 (en) Structures and methods for gene therapy
WO2022260678A1 (en) Compositions and methods for biological delivery vehicles
JP2012533587A (ja) 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
US9976142B2 (en) Targeting molecule and a use thereof
Zhao et al. Peptide-modified lipid nanoparticles boost the antitumor efficacy of RNA therapeutics
KR20250019772A (ko) 종양 억제인자 및 발암유전자를 조절하기 위한 조성물 및 방법
Hall et al. Peptide/lipid-associated nucleic acids (PLANAs) as a multicomponent siRNA delivery system
TW202241388A (zh) 生物遞送系統
Yang et al. Improved cellular delivery of antisense oligonucleotide for miRNA-21 imaging in vivo using cell-penetrating peptide-based nanoprobes
Nair et al. Size-dependent drug loading, gene complexation, cell uptake, and transfection of a novel dendron-lipid nanoparticle for drug/gene co-delivery
US11890352B2 (en) Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
US20150017098A1 (en) Carrier that targets fucosylated molecule-producing cells
ES2928155T3 (es) Composición de nanoadministración peptídica que se dirige a dos receptores
US20240141345A1 (en) CD70-TARGETED MICELLES ENHANCE HIF2? siRNA DELIVERY AND INHIBIT ONCOGENIC FUNCTIONS IN PATIENT-DERIVED CLEAR CELL RENAL CARCINOMA CELLS
Park Enhancing Cytosolic Delivery and Gene Regulation Activity of Spherical Nucleic Acids
Zhang Electrical Charging of Macromolecules for Targeted Delivery to Cartilage for Applications in Diagnostic Imaging and Drug Delivery
Bell et al. RESEARCH ARTICLE mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446
ALSHAER L’UNIVERSITE PARIS-SACLAY

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220506

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230407